Skip to main content
956 Suchergebnisse für:

Evolocumab 

sortieren nach |
"Aktualität" sortiert die Ergebnisse nach Publikationsdatum. "Relevanz" berücksichtigt auch noch andere Faktoren wie zum Beispiel die Häufigkeit der Suchbegriffe im Text.
  1. 01.04.2024 | News

    Evolocumab

    Paradoxical rise in low-density lipoprotein cholesterol levels
  2. 01.04.2024 | News

    Evolocumab

    Transient hyperthyroidism
  3. 19.03.2024 | Online First

    Association between evolocumab use and slow progression of aortic valve stenosis

    No medications have been reported to inhibit the progression of aortic valve stenosis (AS). The present study aimed to investigate whether evolocumab use is related to the slow progression of AS evaluated by serial echocardiography. This was a …

  4. Open Access 30.01.2024 | OriginalPaper

    Evolocumab-Based LDL-C Management in High and Very High Cardiovascular Risk Patients in German Clinical Practice: The HEYMANS Study

    This article is published with digital features, including a graphical abstract, to facilitate understanding of the article. To view digital features for this article, go to https://doi.org/10.6084/m9.figshare.24657735 .

  5. 01.12.2023 | News

    Evolocumab

    Thyroid storm
  6. 01.12.2023 | News

    Evolocumab

    Acute and intermittent transaminitis
  7. 08.12.2023 | OriginalPaper

    Real-world effectiveness and safety of evolocumab in very high-risk atherosclerotic cardiovascular disease patients with acute ischemic stroke

    Based on national stroke statistics in 2019, the age-standardized mortality rate of cerebrovascular disease in China was 149.49/100,000, accounting for 22% of total deaths. Acute ischemic stroke (AIS) constituted about 80% of cerebrovascular …

  8. Open Access 31.07.2023 | OriginalPaper

    Evolocumab effectiveness in the real-world setting: Austrian data from the pan-European observational HEYMANS study

    Cardiovascular disease (CVD) is the most frequent cause of death in Austria, claiming 31,403 lives in 2021 [ 1 ]. One of the main risk factors for CVD is high low-density lipoprotein cholesterol (LDL-C), which is associated with increased …

  9. Open Access 01.12.2023 | OriginalPaper

    Methodology and results of cost-effectiveness of LDL-C lowering with evolocumab in patients with acute myocardial infarction in China

    Acute myocardial infarction (AMI) is the most severe cardiovascular disease (CVD) expression. Despite significant improvements in prognosis over the past decade, it remains one of the leading causes of morbidity and mortality worldwide, with more …

  10. Open Access 07.10.2023 | OriginalPaper

    Real-World Insights into Evolocumab Use in Patients with Hyperlipidemia Across Five Countries: Analysis from the ZERBINI Study

    This article is published with digital features, including a graphical abstract, to facilitate understanding of the article. To view digital features for this article, go to https://doi.org/10.6084/m9.figshare.24174990 .

  11. 01.08.2023 | News

    Evolocumab

    Nephrotic syndrome: case report
  12. Open Access 01.12.2023 | OriginalPaper

    Evolocumab attenuate pericoronary adipose tissue density via reduction of lipoprotein(a) in type 2 diabetes mellitus: a serial follow-up CCTA study

    The prevalence of diabetes mellitus is increasing worldwide due to a growing obesity epidemic and an aging population [ 1 ]. Approximately 90–95% of the diabetes population are classified as type 2 diabetes mellitus (T2DM). Patients with T2DM have …

  13. 01.03.2023 | News

    Evolocumab

    Lack of efficacy: case report
  14. 01.01.2023 | News

    Evolocumab

    Neurocognitive symptoms : case report
  15. 01.10.2022 | News

    Evolocumab

    Pneumonitis: case report
  16. 25.04.2022 | OriginalPaper

    Comparison of Evolocumab and Ezetimibe, Both Combined with Statin Therapy, for Patients with Recent Acute Coronary Syndrome: A Cost-Effectiveness Analysis from the Chinese Healthcare Perspective

    Acute coronary syndrome (ACS) has become one of the most serious threats to the health of people in China. The China cholesterol education program (CCEP) expert advice for the management of dyslipidemias to reduce cardiovascular risk (2019) has …

  17. 01.09.2022 | News

    Evolocumab

    Lack of efficacy: case report
  18. Open Access 21.02.2023 | OriginalPaper

    Efficacy and Safety of Evolocumab in Chinese Patients with Primary Hypercholesterolemia and Mixed Dyslipidemia: 12-Week Primary Results of the HUA TUO 华佗 Randomized Clinical Trial

    This article is published with digital features, including a graphical abstract, to facilitate understanding of the article. The abstract is also available in both Chinese and Japanese. To view all features for this article go to …

  19. 01.04.2022 | News

    Evolocumab

    Increased blood creatine phosphokinase and myopathy: case report
  20. 12.11.2022 | OriginalPaper

    Cost-Effectiveness of Evolocumab in Adult Patients with Atherosclerotic Cardiovascular Disease from Chinese Healthcare Perspective

    Atherosclerotic cardiovascular disease (ASCVD) refers to a series of diseases caused by atherosclerosis, of which myocardial infarction (MI), a type of coronary heart disease (CHD), and ischemic stroke (IS) are the most common and serious diseases …

Suchergebnisse filtern:

e.Medpedia

Proproteinkonvertase Subtilisin/Kexin Typ 9

Lexikon der Medizinischen Laboratoriumsdiagnostik
Proproteinkonvertase Subtilisin/Kexin Typ 9

weitere e.Medpedia Einträge

Suchoperatoren:

„ ... ... “ Findet Dokumente mit genau dieser Wortgruppe in exakt dieser Schreibweise und Reihenfolge (z.B., "rheumatische Beschwerden").
AND / UND Findet Dokumente, in denen beide Begriffe zusammen vorkommen (z.B., alkohol UND demenz).
OR / ODER Findet Dokumente, in denen einer der beiden oder beide Begriffe vorkommen (z.B., hiv ODER aids).
Leerzeichen Findet Dokumente, in denen alle Begriffe vorkommen. Der Leerschritt wird als UND interpretiert (z.B., isolierte systolische hypertonie).
NOT / NICHT Findet Dokumente, in denen der Begriff nach NOT nicht vorkommt (z.B., sars NOT sars-cov-2).
COUNT(...)>n Findet Dokumente, in denen der gesuchte Begriff mehr als n mal vorkommt. n steht für eine beliebige Anzahl (z.B., COUNT(mammakarzinom)>8).
NEAR(..., ..., ) Findet Dokumente, in denen beide Begriffe in beliebiger Reihenfolge innerhalb von maximal n Worten zueinander stehen. Empfehlung: wählen Sie zwischen 15 und 30 als maximale Wortanzahl (z.B., NEAR(covid, diabetes,20)).
* Findet Dokumente, in denen der Begriff in Wortvarianten vorkommt, wobei diese VOR, HINTER oder VOR und HINTER dem Suchbegriff anschließen können (z.B., thrombose*, *thrombose, *thrombose*).
? Findet Dokumente mit dem Suchbegriff in verschiedenen Schreibweisen, hier mit s oder z, also organisation und organization. Das ? steht für eine einzige Stelle (z.B., organi?ation).
& + - Sonderzeichen werden als UND interpretiert (z.B., Diagnose + Therapie).

Sie können Operatoren mit Ihrer Suchanfrage kombinieren, um diese noch präziser einzugrenzen.

Fahren Sie mit der Maus über den Suchoperator, um eine Erklärung seiner Funktionsweise anzuzeigen.